Stock SOBI SWEDISH ORPHAN BIOVITRUM AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Swedish Orphan Biovitrum AB

Equities

SOBI

SE0000872095

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:53 2024-05-24 am EDT 		5-day change 1st Jan Change
280.2 SEK 0.00% Intraday chart for Swedish Orphan Biovitrum AB +1.16% +4.94%
May. 24 Sobi North America Gets FDA Fast Track Designation for Rheumatic Disease Complication Treatment DJ
May. 14 Swedish Orphan Biovitrum AB Elects Zlatko Rihter as New Board Member CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's high margin levels account for strong profits.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • With a 2024 P/E ratio at 28.56 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • The company's enterprise value to sales, at 4.48 times its current sales, is high.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+4.94% 8.94B
B+
CSL LIMITED Stock CSL Limited
-2.00% 90.02B
A-
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-1.18% 39.15B
A-
BIOGEN INC. Stock Biogen Inc.
-15.83% 31.71B
B-
UCB Stock UCB
+62.86% 26.47B
A
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-21.68% 14.34B
C
INCYTE CORPORATION Stock Incyte Corporation
-8.73% 12.89B
B-
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-15.05% 11.18B
D+
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-45.69% 10.97B
B
ALTEOGEN INC. Stock ALTEOGEN Inc.
+96.04% 7.49B
D
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. SOBI Stock
  4. Ratings Swedish Orphan Biovitrum AB